Catena Technologies today announced that Sydney-based fund manager PM Capital has selected its Trace trade repository gateway product to report OTC derivatives trades to the Australian Securities and Investments Commission.
“Catena’s TRACE system will enable the firm to meet the upcoming industry-wide OTC derivative trade reporting compliance obligations quickly and efficiently,” said Ben Skilbeck, Chief Executive Officer for PM CAPITAL. “TRACE not only takes care of our immediate OTC trade reporting requirements for near-term reporting implementation deadlines, but it will also help us to manage additional anticipated future OTC reporting regulatory requirements as they are confirmed. It was important in our selection of TRACE that Catena demonstrate leading knowledge in the OTC trade reporting area as well as the ability to work flexibly within a fund management systems environment. We are looking forward to working with the Catena team throughout current and future implementations.”
Catena Technologies’ TRACE product enables financial institutions to report OTC derivatives trades to regulators via trade repositories. The system captures, enriches and transforms derivatives trade information, automatically submits the required information to the trade repositories, and manages the end-to-end workflow and reconciliation between the trade repositories and a firm’s trading systems. TRACE aligns with the major trade reporting initiatives in Asia Pacific, including those in Japan, Hong Kong, Singapore, and Australia.
“The Catena team is excited to be working with PM CAPITAL to help the firm meet its current and future trade reporting compliance requirements,” said Aaron Hallmark, CEO of Catena Technologies. “Like many buy-side firms with derivatives operations in Asia Pacific, PM CAPITAL has recognized the importance of automating and streamlining the operations related to OTC derivatives reform. Catena looks forward to working with PM CAPITAL and other buy-side firms throughout the region to continue to meet the changing requirements in OTC reform.”